***************
Surgery and Orthopedics Poster Session






Abstract

Introduction

Materials & Methods

Results

Discussion & Conclusion

References




Discussion
Board

INABIS '98 Home Page Your Session Symposia & Poster Sessions Plenary Sessions Exhibitors' Foyer Personal Itinerary New Search

Report of Cancer Exchange System. Year of 1997. Central Registry.


Contact Person: Andres Gonzalez-Navarro (andresgonzalez@mad.servicom.es)


Introduction

The first project of Tumors Registry began in February 1989. In January 1990 we started a pilot program in the Gregorio Marañón Hospital and San Carlos Universitary Hospital. At the same time we developed a software model. This software was demostrated in November 1990 at M.D.Anderson Cancer Center. Department of Patients Studies. Vincent F. Guinee. MD. PhD.

At the begining of 1991 we began to register the data of tumors of these two large hospitals in software model form. Since 1993 five large hospital collected data In our system.

Back to the top.


Materials and Methods

We are using information from Pathology Department, Medical Record Department and Outpatient Department. In each Hospital we have some variations of these sources because of their characteristics The collection data is made in the same format in all hospitals. The data is kept on a filing card and computer base, generating a data base to be used in computer programs very easily. With this software and this data base, the hospital is capable to doing quality control and follow-ups. The hospital registries, periodically send data base to Central Registry where we do studies, external quality control, statistics and reports.

The Central Registry has maintained the data manual, supervised data entry and quality control, created and maintained computer software, and provided overall coordination. The Central Registry has assumed a role of spoksmen in International liason especially with the International Cancer Patient Data Exchange System (UICC).

Back to the top.


Results

Until December, 31, 1997. We have registered 21.946 tumors from five large hospitals.

In this first part of report we analyze the data base called "treatment". This data base has the following structure:

Previous diagnosis and/or treatment elsewhere. Most valid basis of diagnosis of cancer in other institution.Treatment in other institution. Anatomical site. Topography (ICD-O). Histological type. Morphology (ICD-O). Multiple primaries. Clinical extent of disease before treatment. Initial treatment at reporting institution.Most valid basis of diagnosis of cancer at reporting institution.

TABLE I: Tumors recorded by quarter.

JAN-MAR APR-JUN JUL-SEP OCT-DEC TOTAL
1991 - 1160 364 245 1769
1992 564 326 77 269 1236
1993 638 818 584 721 2761
1994 833 967 541 1179 3520
1995 1179 802 681 631 3293
1996 1335 1204 936 1333 4808
1997 766 970 670 1070 3476

A analysis of more important item shows very important information. We analize only the following items: Anatomical site. Topography (ICD-O). Histological type. Morphology (ICD-O). Clinical extent of disease before treatment. Initial treatment at reporting institution. Most valid basis of diagnosis of cancer at reporting institution.

Primary cancer site.

We have put in the appropriate code according to the ICD-O (1976), topography section.

TABLE II. Most frequently topography.

Topography Male Female Frequency Percentage
Esophagus (150) 254 (92,4%) 21 (7,6%) 275 1,3%
Stomach (151) 746 (60,2%) 494 (39,8%) 1240 5,8%
Colon (153) 783 (51,0%) 751 ((49,0%) 1534 7,1%
Rectum (154) 664 (56,3%) 516 (43,7%) 1180 5,5%
Liver (155) 251 (77,0%) 75 (23,0%) 326 1,5%
Larynx (161) 750 (96,5%) 27 (3,5%) 777 3,6%
Lung (162) 2148 (90,6%) 222 (9,4%) 2370 11,0%
Breast (174) - 2646 (100%) 2646 12,3%
Cervix (180) - 580 (100%) 580 2,7%
Uterus (182) - 553 (100%) 553 2,6%
Ovary (183) - 343 (100%) 343 1,6%
Prostate (185) 1006 (100%) - 1006 4,7%
Bladder (188) 1276 (84,7%) 231 (15,3%) 1507 7%
Brain (191) 315 (61,8%) 195 (38,2%) 510 2,4%
TOTAL 9259 7255 16514 76,8%

TABLE III. Basic list. ICD.O. Topography.

Primary Cancer Site Frequency Primary Cancer Site Frequency
Lip (140) 239 (1,1%) Thymus, Heart and Mediastinum (164) 38 (0,2%)
Tongue (141) 243 (1,1%) Hematopoietic System (169) 1467 (6,8%)
Major Salivary Gland (142) 74 (0,3%) Bone and Joints (170) 116 (0,5%)
Gum (143) 56 (0,3%) Connective Tissue (171) 136 (0,6%)
Floor of Mounth (144) 116 (0,5%) Skin (173) 1087 (5,1%)
Others of Mounth (145) 130 (0,6%) Breast Female (174) 2646 (12,3%)
Oropharyx (146) 163 (0,8%) Breast Male (175) 24 (0,1%)
Nasopharynx (147) 95 (0,4%) Uterus (179) 3 (,1%)
Hypopharynx (148) 132 (0,6%) Cervix (180) 580 (2,7%)
Pharinx, ill-defined (149) 28 (0,1%) Corpus (182) 53 (2,6%)
Esophagus (150) 275 (1,3%) Ovary (183) 343 (1,6%)
Stomach (151) 1240 (5,8%) Other Female Genital (184) 130 (0,6%)
Small IIntestine (152) 61 (0,3%) Prostate (185) 1006 (4,7%)
Colon (153) 1534 (7,1%) Testis (186) 79 (0,4%)
Rectum(154) 1180 (5,5%) Other Male Genital (187) 42 (0,2%)
Liver (155) 326 (1,5%) Urinary Bladder (188) 1507 (7,0%)
Gall-Bladder (156) 212 (1,0%) Kidney (189) 417 (1,9%)
Pancreas (157) 226 (1,1%) Eye and Orbit (190) 11 (0,5%)
Peritoneum (158) 72 (0,3%) Brain (191) 510 (2,4%)
Ill-defined sites Digestive (159) 8 (0,0%) Other Tumours of the CNS (192) 149 (0,7%)
Nasal Cavities (160) 55 (0,3%) Thyroid (193) 252 (1,2%)
Larinx (161) 777 (3,6%) Other Endocrine Gland (194) 103 (0,5%)
Lung (162) 2370 (11,0%) Ill-defined, Lymph Nodes (195-6) 28 (0,1%)
Pleura (163) 37 (0,2%) Unknown Primary Site (199) 491(2,3%)
TOTAL 21496

Histological type.

We have put in the appropriate morphology code for a reportable malignant neoplasm according to the ICD-O (1976), morphology section. Allowable histology codes for malignant neoplasm are limited to those for which the fifth digit "behavoir code" is equal or greater that 2. In five histological categories, we registered a 59% of tumors. Others categories have only little quantities.

TABLE IV. Most frequently histology.

Code Frequency Percentage
Adenocarcinoma NOS 8140/3 5399 25,1%
Squamous cell carcinoma. NOS 8070/3 3630 16,9%
Transitional cell carcinoma. NOS 8120/3 1188 5,5%
Carcinoma.NOS 8010/3 510 2,4%
Infiltrating duct carcinoma 8500/3 1999 9,3%
TOTAL 12726 59,2%

TABLE V. Basic list. ICD.O. Morphology.

Morphology Code Frequency Percentage
Neoplasms.NOS 800 244 1,1%
Epithelial neoplasms 801-804 1489 6,9%
Papillary and squamous 805-808 4208 19,6%
Basal cell 809-811 348 1,6%
Transitional cell, papillomas 812-813 1511 7,0%
Adenomas and adenocarcinomas 814-838 6736 31,3%
Cystic,mucinous and serous 844-849 715 3,3%
Ductal, lobular and medullary 850-854 2316 10,8%
Complex epithelial neoplasms 856-858 57 0,3%
Nevi and melanomas 872-879 409 1,9%
Soft tissue and sarcomas. NOS 880 34 0,2%
Fibro, mixo,complex, neoplasms. 881-905 338 1,6%
Germ cell neoplasms 906-909 86 0,4%
Gliomas 938-948 49 2,1%
Linfomas NOS or diffuse 959-963 731 3,4%
Hodgkin, s disease 965-966 284 1,3%
Leukemias 980-994 420 1,9%
Miscellaneous morphology 823 3,8%
Without histológic confirmation 999 298 1,4%

Extent of Disease Before Treatment.

In this item we register the extent of disease at the moment of diagnostic at reporting institution. We have been using only the categories 2,4,and 6 of the item 16 of the system manual of UICC. This decision was take by consensus of the members of Cancer Exchange Data System (CEDS).

The category in situ is reported by behaviour code /2 of ICD-O, morphology section. At the present we can not register TNM Classification.

TABLE VI. Extent of Disease. Excluded Luekemias and Lymphomas.

Frequency Percentage
In situ 293 1,4%
Localized 10720 54,2
Regional 5326 26,9
Distant 3278 16,6
Unknown 150 0,8
Total 19767 91,9

Initial Course of Therapy at the Reporting Institution.

We have considered that the initial course of therapy include all cancer directed treatments administered. This consideration includes the sequence treatment.

TABLE VII: Initial Course of Therapy .
Treatment Nº1 Treatment Nº2 Treatment Nº3
No 1178 ((5,5%) 14933 (69,5%) 20324 (94,5%)
Surgery 12289 (57,2%) 267 (1,2%) 38 (0,2%)
Radiotherapy 2866 (13,3%) 2945 (13,7%) 524 (2,4%)
Bone Marrow Trasplantation 31 (0,1%) 47 (0,2%) 16 (0,1%)
Chemotherapy 2606 (12,1%) 2696 (12,5%) 443 (2,1%)
Hormonotherapy 468 (2,2%) 419 (1,9%) 136 (0,6%)
Inmunotherapy 22 (0,1%) 144 (0,7%) 7 (0,0%)
Paliative care 1782 (8,3%) 17 (0,1%) 6 (0,0%)
Other Therapies 159 (0,7%) 27 (0,1%) 2 (0,0%)
Unknow 33 (0,2%) 1 (0,0%) -
Total treatment patients 20318

(94,5%)

6563

(30,5%)

1172

(5,5%)

In this part of report we analyze the data base called "patients". This data base has the following structure: National Identification Number. First name and surname. Sex. Date of Birth. Site of Birth. Address. We analized only sex and age.

Sex and Age.

TABLE VIII. Sex and Age.

Age Male Female Total Percentage
<30 472 (3,9%) 465 (5,0%) 937 4,4%
30-39 442 (3,6%) 647 (6,9%) 1089 5,1%
40-49 982 (8,1%) 1251 (13,4%) 2233 10,4%
50-59 2200 (18,1%) 1676 (17,9%) 3876 18,0%
60-69 3835 (31,6%) 2163 (23,1%) 5998 27,9%
70-79 2984 (24,6%) 1963 (21,0%) 4947 23,0%
=>80 1213 (10,0%) 1203 (12,8%) 2416 11,2%
TOTAL 12.128 (56,4%) 9.368 (43,6%) 21496 100%

The medium age is 64,5 year, with a mode of 61,5 years. The 73% of the patients are more of 55 years old.

In the last part of report we analyze the data base called "follow-up". This data base has the following structure: Date of Dead. Cause of Dead. International Classification of Cause of Dead. Autopsy. Vital Satus.

Follow Up.

In each hospital our systems is conected with the Outpatient Department and with Medical Record Department. We have directly conexion with data base of these department and in this form we have capable to do a first follow-up. Each year, and mounth by mounth, by listed all the tumors without follow-up and send a letter for

three times and finally if we does not have answer, we telephone.

At same time we registered the Cause of Death according to the Ninth Revision of the International Classification of Disease (ICD).

TABLE IX: Cause of Death.

Frequency Percentage
Alive 12259 57,0%
Tumor 8460 39,4%
Clinical Complications 371 1,7%
Treatment Toxicity 8 0,0%
No Related 384 1,8%
Unknow 14 0,1%
Dead 9237 43,0%

TABLE X: Dead for Primary Site.
Primary Site First Year Second Year Rate Mort/Morb
Lung 1208 (51%) 345 (14,6%) 0,65
Breast 116 (4,4%) 146 (5,5%) 0,15
Prostate 130 (12,9%) 99 (9,8%) 0,22
Bladder 209 (13,9%) 131 (8,7%) 0,26
Esophagus 163 (59,3%) 39 (14,2%) 0,73
Stomach 552 (44,5%) 110 (8,9%) 0,53
Colon 382 (24,9%) 151 (9,8%) 0,34
Rectum 257 (21,8%) 142 (12,0%) 0, 26

The esophagus cancer is the more letal tumor. Is more frecuent that other and dead rate is very high.

TABLE XI. Disease Status of Patient at Annual Contact.
One year Two year Three year Four year
Not Applicable 5,5% 38,2% 54,9% 71,1%
Alive without disease 11,4% 6,3% 2,6% 1,7%
Alive with tumor 20,6% 10,4% 6,3% 3,3%
Alive 32,6% 29,3% 25,5% 18,6%
Dead 24,7% 9,4% 4,3% 2,1%
Unknow 5,1% 6,4% 2,9% 2,2%
Lost - - 3,3% 1,0%

Back to the top.


Discussion and Conclusion

These data suggest that hospital cancer register statistics can be used to assess cancer patients care for hospital cohorts of patients. The 10 cancer anatomic site most commonly reported were breast (12,3%), lung (11%), colon (7,1%), bladder (7%) and stomach (5,8%). But the most important cause of death were esophagus (73%) and lung (65%). The survival value is 63 months, (95% confidence interval; 60/67), using the Kaplan-Meyer test.

In medical practice, the data of tumor register serves many purposes. It helps clinicians analizy outcomes, evaluate results therapy, and assess the results of early cancer detection. Highligths of these reports is inform physician actively involved in the care of cancer patients of the latest findings.

Back to the top.


References

1. Oficina Regional de Coordinación Oncologica. Sistema de Intercambio de Datos en Cáncer. Manual de Procedimientos. 1992. Madrid. Consejeria de Salud.

2. Maclennan R, Muir CC, Steinitz R, Winkler A. Cancer Registration and its techiques. IARC. 1978. Lyon. Scientific Publications nº 21.

3. Jensen OM, Parquin DM, Maclennan R, Muir CS, Skeets R. Cancer Registration, principles and methods. IARC 1991. Lyon. Scientific Publications nº 95.

4. Organizacion Panamericana de la Salud. World Health Organization. Clasificación Internacional de Enfermedades para Oncologia (CIE-O). OPS. 1977 Washington. Publicación Cientifica nº 345.

5. Organizacion Panamericana de la Salud. World Health Organization. Clasificación Internacional de Enfermedades (CIE-9). OPS. 1978 Washington. Publicación Cientifica nº 353.

6. Menck H, Smart C. Central Cancer Registries. Design, Management and Use. 1994. Harwood Academic Publisers. Switzerland.

7. Parkin DM, Chen VW, Ferlay J, Galceran J, Storm HH and Whelan SL. Comparabilidad y Control de calidad en los registros de Cáncer. Lyon, 1995. IACR. IARC Informe Técnico nº 19.

Back to the top.


| Discussion Board | Previous Page | Your Poster Session |
Gonzalez-Navarro, A; Gonzalez-Hernandez, MJ; (1998). Report of Cancer Exchange System. Year of 1997. Central Registry.. Presented at INABIS '98 - 5th Internet World Congress on Biomedical Sciences at McMaster University, Canada, Dec 7-16th. Available at URL http://www.mcmaster.ca/inabis98/surgeryortho/gonzalez-navarro0709/index.html
© 1998 Author(s) Hold Copyright